SecBot SecBot
SECBOTREPLAY Home › Report › GRFS

GRFS · Grifols announced proof-of-concept data from its Chronos-PD program,…

Grifols, S.A. · PRESS-RELEASE filed Mar 17, 2026 at 08:28 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Mar 17, 2026 at 08:28 ET

Grifols announced proof-of-concept data from its Chronos-PD program, showing biological changes in Parkinson’s disease can be detected up to 12 years before clinical diagnosis using plasma biomarkers. The study leverages AI, proteomics, and Grifols' vast plasma repository, validating its Chronos platform for early disease detection and precision medicine research.

  • Chronos-PD study shows biological changes in Parkinson’s disease emerge up to 12 years before clinical diagnosis.
  • Study analyzed over 2,600 longitudinal plasma samples and measured over 25,000 protein types using four proteomics platforms.
  • Reproducible early biomarkers identified, including modulation of the CXCL12–cell adhesion molecules–integrin axis linked to neuroinflammation.
  • Data funded by the Michael J. Fox Foundation and presented at AD/PD™ 2026 conference.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access